Exagen（E08A）株式概要米国ではAVISEブランドで各種検査製品の企画・開発・販売を行っています。 詳細E08A ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長1/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より79.1%で取引されている 収益は年間9.68%増加すると予測されています アナリストらは、株価が103.4%上昇するだろうとほぼ一致している。 リスク分析過去3か月間に大規模なインサイダー売却が発生 現在は利益が出ておらず、今後3年間で利益が出る見込みはない German市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るE08A Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€3.6259.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-45m109m2016201920222025202620282031Revenue US$108.5mEarnings US$19.7mAdvancedSet Fair ValueView all narrativesExagen Inc. 競合他社Genetic AnalysisSymbol: DB:8V8Market cap: €42.7mDarwinSymbol: MUN:7V0Market cap: €74.4mFormyconSymbol: XTRA:FYBMarket cap: €354.3m2investSymbol: XTRA:2INVMarket cap: €62.9m価格と性能株価の高値、安値、推移の概要Exagen過去の株価現在の株価US$3.6252週高値US$10.2052週安値US$2.26ベータ1.811ヶ月の変化48.36%3ヶ月変化32.12%1年変化-30.38%3年間の変化27.46%5年間の変化-68.79%IPOからの変化-76.78%最新ニュースお知らせ • May 11Exagen Inc. Reaffirms Earnings Guidance for the full year 2026Exagen Inc. reaffirmed earnings guidance for the full year 2026. The company continues to expect full-year 2026 revenue of $70 million to $73 million.お知らせ • Apr 28Exagen Inc., Annual General Meeting, Jun 09, 2026Exagen Inc., Annual General Meeting, Jun 09, 2026. Location: training room, 2175 salk avenue, 3rd floor, carlsbad, california 92008, United Statesお知らせ • Apr 27Exagen Inc. to Report Q1, 2026 Results on May 11, 2026Exagen Inc. announced that they will report Q1, 2026 results Pre-Market on May 11, 2026お知らせ • Mar 10Exagen Inc. Provides Earnings Guidance for Full Year 2026Exagen Inc. provided earnings guidance for full year 2026. For the year, the company expects revenue of $70 million to $73 million.お知らせ • Feb 24Exagen Inc. to Report Q4, 2025 Results on Mar 10, 2026Exagen Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 10, 2026お知らせ • Jan 12Exagen Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025Exagen Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. For the quarter, the company expects Total Revenue to be $16 million to $17 million. For the year, the company expects Total Revenue to be $66 million to $67 million. Record full year 2025 revenue, an increase of at least 19% over 2024.最新情報をもっと見るRecent updatesお知らせ • May 11Exagen Inc. Reaffirms Earnings Guidance for the full year 2026Exagen Inc. reaffirmed earnings guidance for the full year 2026. The company continues to expect full-year 2026 revenue of $70 million to $73 million.お知らせ • Apr 28Exagen Inc., Annual General Meeting, Jun 09, 2026Exagen Inc., Annual General Meeting, Jun 09, 2026. Location: training room, 2175 salk avenue, 3rd floor, carlsbad, california 92008, United Statesお知らせ • Apr 27Exagen Inc. to Report Q1, 2026 Results on May 11, 2026Exagen Inc. announced that they will report Q1, 2026 results Pre-Market on May 11, 2026お知らせ • Mar 10Exagen Inc. Provides Earnings Guidance for Full Year 2026Exagen Inc. provided earnings guidance for full year 2026. For the year, the company expects revenue of $70 million to $73 million.お知らせ • Feb 24Exagen Inc. to Report Q4, 2025 Results on Mar 10, 2026Exagen Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 10, 2026お知らせ • Jan 12Exagen Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025Exagen Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. For the quarter, the company expects Total Revenue to be $16 million to $17 million. For the year, the company expects Total Revenue to be $66 million to $67 million. Record full year 2025 revenue, an increase of at least 19% over 2024.お知らせ • Nov 05Exagen Inc. Reiterates Earnings Guidance for the Year 2025Exagen Inc. reiterated earnings guidance for the year 2025. For the year, the company expects revenue of between $65 million and $70 million, and at the high end of the revenue range would expect to achieve positive adjusted EBITDA in the fourth quarter of 2025.お知らせ • Oct 22Exagen Inc. to Report Q3, 2025 Results on Nov 04, 2025Exagen Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 04, 2025お知らせ • Jul 29Exagen Inc. Provides Earnings Guidance for the Full Year 2025Exagen Inc. provided earnings guidance for the full year 2025. For the year, company expects 2025 full-year revenue of between $65 million and $70 million, and at the high end of the revenue range would expect to hit positive adjusted EBITDA in the fourth quarter.お知らせ • Jul 18Exagen Inc. Appoints Charles S. McKhann as A Class III Director and to the Compensation Committee and Nominating Committee, Effective July 17, 2025Exagen Inc.'s board of directors on July 17, 2025, upon the recommendation of the Nominating and Corporate Governance Committee pursuant to the bylaws of the Company, appointed, effective as of July 17, 2025, Charles S. McKhann to serve as a Class III director, with an initial term expiring at the Company’s 2028 annual meeting of stockholders. In connection with and effective as of his appointment to the Board, Mr. McKhann was also appointed to the Compensation Committee of the Board and the Nominating Committee. Also in connection with his appointment, the size of the Board was increased from seven (7) members to eight (8) members, effective as of the Effective Date. Mr. McKhann served as the President, Chief Executive Officer, and a member of the board of directors of Silk Road Medical Inc., a medical device company, from November 2023 to September 2024, when Silk Road was purchased by Boston Scientific Corporation, and served as Chief Executive Officer, President and a member of the Board of Directors of Apollo Endosurgery Inc., a medical device company, from March 2021 to April 4, 2023, when Apollo was purchased by Boston Scientific. From October 2017 to December 2018, Mr. McKhann served as Chief Commercial Officer at ROX Medical Inc., a medical device company. From July 2016 to April 2017, he served as Chief Commercial Officer of Torax Medical Inc., a medical device company acquired by Johnson & Johnson in April 2017. From January 2015 to July 2016, he served as Chief Commercial Officer of Intersect ENT Inc., a medical device company. In addition, from September 2012 to March 2021, he served as Managing Director of Vernon Consulting Inc. Mr. McKhann holds a B.A. in Political Sciences and Economics and an M.B.A. from Stanford University.お知らせ • Jul 16Exagen Inc. to Report Q2, 2025 Results on Jul 29, 2025Exagen Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 29, 2025お知らせ • Jun 23Exagen Inc. Appoints Michael Mahler as Chief Scientific OfficerExagen Inc. announced the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune research. At the same time, Dr. Mahler initiated a productive and lasting collaboration with one of his mentors, Dr. Marvin J. Fritzler, a thought leader in the field whose research spans a wide range of topics, including autoimmune disease, the biology of autoantigens, and novel diagnostic technologies. Over the course of his distinguished career, Dr. Mahler has held key positions at various diagnostic companies, most recently serving as Senior Vice President of Research Development and Business Development at Werfen. His transformative work has led to the discovery of several novel autoantigens and the development of innovative diagnostic solutions. His scientific contributions have resulted in over 300 peer-reviewed publications and numerous patents, advancing the accurate diagnosis of autoimmune diseases. In his new role at Exagen, Dr. Mahler will spearhead strategic initiatives aimed at enhancing precision diagnostics for autoimmune diseases. His expertise will support Exagen's development of cutting-edge tools to improve patient outcomes.お知らせ • May 09Exagen Inc. has completed a Follow-on Equity Offering in the amount of $17.5875 million.Exagen Inc. has completed a Follow-on Equity Offering in the amount of $17.5875 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,350,000 Price\Range: $5.25 Discount Per Security: $0.315お知らせ • May 08Exagen Inc. has filed a Follow-on Equity Offering.Exagen Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stockお知らせ • May 06Exagen Inc. Provides Earnings Guidance for Full Year 2025Exagen Inc. provided earnings guidance for full year 2025. For the full-year, the company expects revenue of at least $65 million.お知らせ • May 01Exagen Inc., Annual General Meeting, Jun 10, 2025Exagen Inc., Annual General Meeting, Jun 10, 2025. Location: exagen administrative offices, training room, 2175 salk avenue, 3rd floor,california 92008., carlsbad United Statesお知らせ • Apr 22Exagen Inc. to Report Q1, 2025 Results on May 05, 2025Exagen Inc. announced that they will report Q1, 2025 results Pre-Market on May 05, 2025お知らせ • Mar 12Exagen Inc. Provides Earnings Guidance for First Quarter of 2025Exagen Inc. provides earnings guidance for first quarter of 2025. For the period, the company expects total revenue of at least $14.5 million. The company expects to provide its full-year 2025 financial outlook in connection with the release of its first quarter 2025 financial results.お知らせ • Feb 26Exagen Inc. to Report Q4, 2024 Results on Mar 11, 2025Exagen Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 11, 2025お知らせ • Jan 13Exagen Inc. Secures Conditional Ny State Approval for New Lupus and Rheumatoid Arthritis BiomarkersExagen Inc. announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays, with a planned commercial launch in January 2025. New AVISE CTD Biomarkers, The company’s new SLE and RA biomarkers will be incorporated into the AVISE CTD platform. Collectively, the company expects these new biomarkers will further improve the clinical utility of AVISE CTD, and provide clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. The new biomarkers are as follows: T-Cell Lupus profile comprises new biomarkers; TC4d, TIgG, and TIgM. These markers provide superior sensitivity for SLE compared to conventional SLE biomarkers, further enhancing their AVISE Lupus profile for a more comprehensive diagnosis, particularly in clinically ambiguous cases. RA profile includes additional anti-RA33 biomarkers; IgA, IgG, and IgM. These markers provide clinicians with more data to confidently identify patients with RA and substantiate a seronegative RA diagnosis.お知らせ • Nov 15Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD PlatformExagen Inc. announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) biomarkers, to be incorporated into the AVISE CTD platform. Collectively, these new biomarkers will further improve the clinical utility of AVISE CTD, providing clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. Since 2012, AVISE CTD has delivered diagnostic clarity where overlapping clinical symptoms and ambiguous disease states make it difficult to arrive at a differential diagnosis of a connective tissue disease (CTD). A lack of diagnostic clarity may lead to serial and repeat testing, increased morbidity, worsening mortality rates and growing healthcare costs. The seven new biomarkers for AVISE CTD are as follows: A new T Cell Lupus profile will include three new T Cell biomarkers (TC4d, TIgG, TIgM). These provide enhanced sensitivity for SLE as compared to conventional SLE biomarkers and serve as a complement to the AVISE Lupus profile also included in the test. · The RA profile will be enhanced with the addition of four biomarkers (anti-CarP and anti-RA33 biomarkers IgA, IgG, IgM). Providers are given more data to confidently identify patients with RA and substantiate a seronegative RA diagnosis. The AVISE CTD test that rheumatologists have come to know and trust is composed of multiple biomarker assays that assist in the clinical diagnosis of the most common CTDs, which included: SLE; RA; Sjögren's Disease; Mixed Connective Tissue Disease (MCTD); Antiphospholipid Syndrome; Myositis; Systemic Sclerosis; Graves’ Disease; Hashimoto’s Thyroiditis. Availability of the AVISE CTD test enhancements are pending conditional approval by the New York State Department of Health. Learn more about AVISE CTD [2] and its ability to provide unique diagnostic clarity.Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.31 loss in 3Q 2023)Third quarter 2024 results: US$0.28 loss per share (improved from US$0.31 loss in 3Q 2023). Revenue: US$12.5m (down 6.8% from 3Q 2023). Net loss: US$5.03m (loss narrowed 7.1% from 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.お知らせ • Nov 13Exagen Inc. Provides Earnings Guidance for the Full Year 2024Exagen Inc. provided earnings guidance for the full year 2024. The company now expected 2024 full-year revenue of $55 million to $56 million, primarily reflecting the impact of one-time adjustments in the third quarter.お知らせ • Oct 30Exagen Inc. to Report Q3, 2024 Results on Nov 12, 2024Exagen Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 12, 2024New Risk • Aug 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (€53.8m market cap, or US$58.8m).Reported Earnings • Aug 06Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.28 loss in 2Q 2023)Second quarter 2024 results: US$0.16 loss per share (improved from US$0.28 loss in 2Q 2023). Revenue: US$15.1m (up 6.6% from 2Q 2023). Net loss: US$2.97m (loss narrowed 41% from 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.お知らせ • Aug 06Exagen Inc. Revises Earnings Guidance for the Full Year 2024Exagen Inc. revised earnings guidance for the full year 2024. Given continued improved performance, the company increasing guidance for full-year 2024 revenue to at least $57 million.お知らせ • Aug 03Exagen Inc. Announces Chief Financial Officer ChangesExagen Inc. announced the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. Mr. Black brings to Exagen more than 30 years of financial and accounting experience, having served in finance leadership roles for eight publicly traded companies. He currently serves as CFO of Standard BioTools, where he recently played a key leadership role in executing its merger with SomaLogic, creating a diversified leader in life science tools. Prior to that, he was CFO of Apollo Endosurgery, where he was instrumental in the Company turnaround and eventual $650 million sale to Boston Scientific. Previously, he spent over four years as CFO of Alphatec Spine, where he successfully closed nearly $500M in financing transactions to support accelerated growth, two strategic acquisitions and expansion of the company market cap from $20M to over $1B during his tenure. Previously to this role, Mr. Black served as Senior Vice President and Chief Financial Officer of Apollo Endosurgery Inc., a publicly traded, medical technology company focused on endoscopic therapies for gastrointestinal conditions and interventional treatment of obesity, from August 2021 until April 2023, when Apollo was acquired by Boston Scientific. Prior to joining Apollo, he served as Executive Vice President and Chief Financial Officer of Alphatec Holdings Inc., a publicly traded, medical technology company focused on the surgical treatment of spinal disorders, from March 2017 to April 2021. Prior to joining Alphatec, Mr. Black was Senior Vice President and Chief Financial Officer of Applied Proteomics Inc., a proteomics-based diagnostics company, Senior Vice President and Chief Financial Officer of AltheaDx Inc., a pharmacogenetics diagnostics company, and Senior Vice President and Chief Financial Officer of Verenium Corporation, an industrial biotechnology company. Mr. Black began his career at Ernst & Young LLP. Mr. Black is a member of the board of directors of Cellana Inc., a privately held company and developer of algae-based bioproducts, where he serves as chairperson of the audit committee. Mr. Black received his B.S. in Business from the University of Arizona.お知らせ • Jul 22Exagen Inc. to Report Q2, 2024 Results on Aug 05, 2024Exagen Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 05, 2024Recent Insider Transactions • May 19CEO, President & Director recently bought €71k worth of stockOn the 16th of May, John Aballi bought around 40k shares on-market at roughly €1.77 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of €16k worth in shares.お知らせ • May 15Exagen Inc. Updates Earnings Guidance for the Full Year 2024Exagen Inc. updated earnings guidance for the full year 2024. For full year 2024 revenue, company is increasing guidance to at least $55 million.Reported Earnings • May 13First quarter 2024 earnings released: US$0.19 loss per share (vs US$0.44 loss in 1Q 2023)First quarter 2024 results: US$0.19 loss per share (improved from US$0.44 loss in 1Q 2023). Revenue: US$14.4m (up 28% from 1Q 2023). Net loss: US$3.36m (loss narrowed 56% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.お知らせ • May 01Exagen Inc. to Report Q1, 2024 Results on May 13, 2024Exagen Inc. announced that they will report Q1, 2024 results at 9:30 AM, US Eastern Standard Time on May 13, 2024お知らせ • Apr 28Exagen Inc., Annual General Meeting, Jun 10, 2024Exagen Inc., Annual General Meeting, Jun 10, 2024, at 06:00 Pacific Standard Time. Location: Exagen Administrative Offices, Training Room, 2175 Salk Avenue, 3rd Floor, Carlsbad California United States Agenda: To elect three directors to serve as Class II directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified; to ratify the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.お知らせ • Apr 27Exagen Inc. Announces Changes in Board of DirectorsExagen Inc. announced changes to the Board of Directors. Exagen announced Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the University of Illinois. He spent over 10 years at the scientific software company, Accelrys, where he held several positions with increasing responsibility including SVP, General Manager and Chief Science Officer. He then joined Illumina as its first Chief Information Officer and spent 12 years with the sequencing leader. He was most recently with LunaPBC as the Chief Information and Privacy Officer. Dr. Kahn currently holds Board positions at Blue Circle Health, Rady Children’s Institute for Genomic Medicine and Rady Children's Hospital. Dr. Kahn received a B.S. in Chemistry from Rider College, a Ph.D. in Theoretical Organic Chemistry from the University of California, Irvine and was a Fellow Commoner at Churchill College and Postdoctoral Fellow at the University of Cambridge, England. Additionally, in an ever-continuing effort to streamline operations at the company, Exagen announced that it is reducing the size of the Board of Directors from nine to seven, a change that has been carefully planned and complements the long-term strategy. Brian Birk, Ebetuel Pallares, Ph.D. and Wendy Johnson have all agreed to step down from the Board of Directors, effective on the date of the annual shareholder meeting on June 10th, 2024.Reported Earnings • Mar 19Full year 2023 earnings released: US$1.34 loss per share (vs US$2.77 loss in FY 2022)Full year 2023 results: US$1.34 loss per share (improved from US$2.77 loss in FY 2022). Revenue: US$52.5m (up 15% from FY 2022). Net loss: US$23.7m (loss narrowed 50% from FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.New Risk • Mar 19New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings are forecast to decline by an average of 2.0% per year for the foreseeable future. Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$30m). Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Shareholders have been diluted in the past year (4.5% increase in shares outstanding). Market cap is less than US$100m (€27.8m market cap, or US$30.2m).お知らせ • Mar 08Exagen Inc. to Report Q4, 2023 Results on Mar 18, 2024Exagen Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 18, 2024お知らせ • Jan 08Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023Exagen Inc. reaffirmed earnings guidance for the full year ended December 31, 2023. For the year, the company expected total revenue of at least $50 million.Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.47 loss in 3Q 2022)Third quarter 2023 results: US$0.31 loss per share (improved from US$0.47 loss in 3Q 2022). Revenue: US$13.4m (down 8.9% from 3Q 2022). Net loss: US$5.42m (loss narrowed 33% from 3Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.お知らせ • Oct 31Exagen Inc. to Report Q3, 2023 Results on Nov 13, 2023Exagen Inc. announced that they will report Q3, 2023 results After-Market on Nov 13, 2023Recent Insider Transactions • Oct 20CEO, President & Director recently sold €56k worth of stockOn the 17th of October, John Aballi sold around 34k shares on-market at roughly €1.65 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite the recent sale, John has been a net buyer over the last 12 months, purchasing a net total of €173k worth of shares.New Risk • Aug 08New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$34m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$34m). Currently unprofitable and not forecast to become profitable over next 3 years (US$26m net loss in 3 years). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€42.0m market cap, or US$46.0m).Reported Earnings • Aug 08Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.86 loss in 2Q 2022)Second quarter 2023 results: US$0.28 loss per share (improved from US$0.86 loss in 2Q 2022). Revenue: US$14.1m (up 86% from 2Q 2022). Net loss: US$5.01m (loss narrowed 66% from 2Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings.New Risk • Aug 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.7% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$26m net loss in 3 years). Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€37.7m market cap, or US$41.4m).お知らせ • Jul 26Exagen Inc. to Report Q2, 2023 Results on Aug 07, 2023Exagen Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 07, 2023お知らせ • Jul 25Exagen Inc. Appoints Paul Kim as Class II DirectorOn July 24, 2023, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the board) of Exagen Inc., and pursuant to the bylaws of the Company, the Board appointed Paul Kim to serve as a Class II director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling the vacancy on the Board. In connection with his appointment to the Board, Mr. Kim was also appointed to the Audit Committee of the Board (the “Audit Committee) and the Compensation Committee of the Board (the Compensation Committee), effective as of July 24, 2023. Following Mr. Kim’s appointment, the Audit Committee consists of Frank Stokes (Chair), Wendy Johnson, Ana Hooker and Paul Kim, and the Compensation Committee consists of Bruce C. Robertson, Ph.D. (Chair), Ana Hooker and Paul Kim. Paul Kim has served as Fulgent Genetic Inc.’s (Fulgent) Chief Financial Officer since January 2016. Prior to his service for Fulgent, Mr. Kim was retired from 2011 until 2015 and served as Chief Financial Officer of Cogent Inc., a publicly traded biometric identification services and product company, from 2004 until 2011. Mr. Kim’s past experience also includes service as the Chief Financial Officer of JNI Corporation, a publicly traded storage area network technology company, from 2002 until 2003, as Vice President, Finance and Corporate Controller at JNI from October 1999 to August 2002 and as Vice President of Finance and Administration for Datafusion Inc., a privately held software development company, from 1998 until 1999. From April 1996 to January 1998, Mr. Kim was the Corporate Controller for Interlink Computer Sciences Inc., a publicly traded enterprise software company. From 1990 to 1996, Mr. Kim worked for Coopers and Lybrand L.L.P., leaving as an audit manager. Mr. Kim received a B.A. in Economics from the University of California at Berkeley in 1989 and is a Certified Public Accountant.Reported Earnings • May 16First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.60 loss in 1Q 2022)First quarter 2023 results: US$0.44 loss per share (improved from US$0.60 loss in 1Q 2022). Revenue: US$11.2m (up 8.0% from 1Q 2022). Net loss: US$7.69m (loss narrowed 25% from 1Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 21Full year 2022 earnings released: US$2.77 loss per share (vs US$1.68 loss in FY 2021)Full year 2022 results: US$2.77 loss per share (further deteriorated from US$1.68 loss in FY 2021). Revenue: US$45.6m (down 5.7% from FY 2021). Net loss: US$47.4m (loss widened 77% from FY 2021). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.お知らせ • Jan 24Exagen Inc. Announces Board ChangesExagen Inc. announced that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board.Dr. Nova currently serves as President of Veracyte's U.S. CLIA business where she leads all aspects of the company's broad menu of diagnostic laboratory tests. She previously held the position of President & CEO of Decipher Biosciences until March 2021, when Veracyte purchased the organization for $600 million. She has held numerous leadership roles in the life science industry, which include CEO of Molecular Stethoscope and SVP & General Manager of Oncology at Illumina. Dr. Nova was the co-founder, President & CEO of Genoptix, which was purchased by Novartis AG for $470 million in 2011. She has also held senior positions with Nanogen Inc., Ligand Pharmaceuticals Inc. and Hybritech. Dr. Nova currently serves on the Board of Azenta and previously served on the Board of Directors of Veracyte and Arena Pharmaceuticals. Dr. Nova holds a Ph.D. in Biochemistry from the University of California, Riverside and a B.S. in Biological Sciences from the University of California, Irvine.お知らせ • Dec 06Exagen Inc. Announces Executive ChangesExagen Inc. announced that on December 5, 2022, Debra Zack, M.D., Ph.D., the company’s Chief Medical Officer, was removed from her position and her employment terminated in connection with the Reduction in Force. Dr. Zack is entitled to severance under that certain Amended and Restated Executive Change in Control and Severance Plan. On December 5, 2022, Mark Hazeltine, the Company’s current Chief Operating Officer was appointed to serve as the Company’s Chief Business Officer. Mr. Hazeltine has served as the company’s Chief Operating Officer since March 2021 and served in multiple key leadership roles including General Manager, Senior Vice President of Finance and Corporate Development, Vice President of Finance, and Senior Director of Financial Planning and Analysis since joining the Company in March 2015. Prior to joining the Company, from September 2010 to March 2015, Mr. Hazeltine served as Director of Financial Planning and Analysis and Director of Financial Business Processes at CareFusion. Mr. Hazeltine also worked in multiple management roles at multinational organizations including Kyocera and Qualcomm. Mr. Hazeltine received a B.A. in Business Administration from the University of San Diego and an M.B.A. from the Marshall School of Business at the University of Southern California.お知らせ • Nov 16Exagen Inc. Increases Revenue Guidance for 2022Exagen Inc. increased revenue guidance for 2022. For the period, the company increases revenue guidance range to $40 million to $43 million.お知らせ • Nov 15Exagen Inc. announced delayed 10-Q filingOn 11/14/2022, Exagen Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 01Exagen Inc. to Report Q3, 2022 Results on Nov 14, 2022Exagen Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 14, 2022お知らせ • Oct 18+ 1 more updateExagen Inc. Appoints John Aballi as PresidentExagen Inc. announced that the company has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm. The Exagen Board has appointed Mr. Aballi as CEO, President, and a member of the Board. Mr. Aballi is an executive with a broad range of experience in growth-stage companies in the clinical diagnostics arena. Most recently he served as SVP, General Manager, Urology & CLIA COO at Veracyte Inc. Mr. Aballi, who has 15 years of diagnostic industry experience, is known for transforming commercial and laboratory operations and has broad experience building efficient clinical diagnostics operations. In his previous role at Veracyte, he was responsible for a business unit of 245 members and led a team that grew the urology unit revenue to $120 million-plus annually. He also led the implementation of CAP standards across the San Francisco and Austin labs and managed Veracyte's CLIA laboratory operations. In his prior position, Mr. Aballi was COO at Decipher Biosciences where he oversaw revenue growth from $12.6 million in 2018 to $39 million in 2020. Mr. Aballi was a key part of the executive team that helped take Decipher from a struggling company to being sold to Veracyte for $600 million in early 2021. He had P&L responsibility for all aspects of operations including sales, quality management, medical operations, customer service, IT, assay development, billing, managed care, internal expansion, and laboratory operations. Mr. Aballi was also responsible for oversight of laboratory operations at Molecular Stethoscope and Genoptix in various senior roles. Mr. Aballi was a Board Member of PFS Genomics in San Diego, a molecular diagnostic company specializing in proprietary signature development in breast cancer, which was acquired by Exact Sciences in 2021. He holds an MBA from California Baptist University and dual degrees from UC San Diego in biochemistry and cell biology and economics. Mr. Aballi will assume his new role at Exagen immediately.お知らせ • Oct 05Exagen Inc. Appoints Andrew L. Concoff as Chief Innovation OfficerExagen Inc. announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as Chief Innovation Officer. In this role, Dr. Concoff will lead the company’s rheumatoid arthritis medical initiatives, including the AVISE® RADR platform (Rheumatoid Arthritis Drug Response). Dr. Concoff will be a key principal in strategy, business development, portfolio management, pipeline prioritization, and formation of new business ventures, as well as the advancement of innovative access partnerships with payors and governments globally. Dr. Concoff has more than fifteen years of clinical practice in rheumatology, having completed his fellowship at the University of California, Los Angeles. He earned a B.S. in Psychobiology from UCLA, an M.D. from the University of Texas Medical School at Houston where he also completed coursework toward a Master’s in Clinical Research. Dr. Concoff joins Exagen from United Rheumatology, where his work as Executive Vice President, Chief Medical Officer enables him to create, model, and implement value-based programs with payors, quality improvement initiatives with pharmaceutical manufacturers, and other clinical care innovations with stakeholders across the musculoskeletal ecosystem. He is also a Fellow of the American College of Rheumatology and has served on numerous national guideline committees, most recently as Chair of the Knee Osteoarthritis and Ultrasound Guideline Committees for United Rheumatology.お知らせ • Sep 02Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 PatientsExagen Inc. announced that its collaboration with Dr. Iñaki Sanz at Emory University has led to a publication in Nature, found here. Exagen’s clinical test offerings, run on samples from severe COVID-19 patients, helped researchers from Emory characterize the autoimmune profiles induced by SARS-CoV-2 infection. In addition, these retrospective analyses laid the groundwork for the recent longitudinal studies of so-called post-acute COVID syndrome (PACS), as well as other post-severe pulmonary infection sequelae, including the incorporation of Exagen’s proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. These efforts will assess the importance of long-term autoimmune monitoring in those patients experiencing lasting symptoms following acute pulmonary infection, including those caused by SARS-CoV-2.Reported Earnings • Aug 06Second quarter 2022 earnings released: US$0.78 loss per share (vs US$0.38 loss in 2Q 2021)Second quarter 2022 results: US$0.78 loss per share (down from US$0.38 loss in 2Q 2021). Revenue: US$8.96m (down 30% from 2Q 2021). Net loss: US$13.3m (loss widened 108% from 2Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 24% growth forecast for the industry in Germany.お知らせ • Aug 06+ 1 more updateExagen Inc. Provides Revenue Guidance for the Year of 2022Exagen Inc. provided revenue guidance for the year of 2022. For the year, the company expected revenue to be in the range of $35 million to $40 million.お知らせ • Jul 22Exagen Inc. to Report Q2, 2022 Results on Aug 04, 2022Exagen Inc. announced that they will report Q2, 2022 results After-Market on Aug 04, 2022Reported Earnings • May 13First quarter 2022 earnings released: US$0.60 loss per share (vs US$0.48 loss in 1Q 2021)First quarter 2022 results: US$0.60 loss per share (down from US$0.48 loss in 1Q 2021). Revenue: US$10.4m (down 1.8% from 1Q 2021). Net loss: US$10.3m (loss widened 65% from 1Q 2021). Over the next year, revenue is forecast to grow 17%, compared to a 37% growth forecast for the industry in Germany.お知らせ • May 12+ 1 more updateExagen Inc. Revises Revenue Guidance for the Full Year of 2022Exagen Inc. revised revenue guidance for the full year of 2022. For the year, the company raises its guidance and expects revenue to be in the range of $53 million to $55 million, compared to previously provided guidance of $51 million to $53 million.お知らせ • Apr 26Exagen Inc. to Report Q1, 2022 Results on May 11, 2022Exagen Inc. announced that they will report Q1, 2022 results After-Market on May 11, 2022Reported Earnings • Nov 11Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.34 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$12.3m (up 14% from 3Q 2020). Net loss: US$7.18m (loss widened 67% from 3Q 2020).Reported Earnings • Aug 11Second quarter 2021 earnings released: US$0.38 loss per share (vs US$0.27 loss in 2Q 2020)The company reported a mediocre second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$12.8m (up 43% from 2Q 2020). Net loss: US$6.41m (loss widened 91% from 2Q 2020).お知らせ • Jul 15Exagen Inc. Announces the Publication of Their Latest Clinical Utility Study in Lupus & Science MedicineExagen Inc. announced the publication of their latest clinical utility study in Lupus & Science Medicine. This multi-center study demonstrated that the AVISE Lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (SLE) in patients suspected of this disease and informed appropriate treatment decisions. In collaboration with 12 rheumatology practices, a systematic and longitudinal review of medical records of patients that received AVISE testing between 2018 and 2020 was performed. Medical records of antinuclear antibody (ANA)-positive patients with a positive or negative AVISE Lupus score were evaluated at three time points: when the test was ordered, when the test results were reviewed, and at least 8 months later. Assessment of the confidence in the diagnosis of SLE and initiation of hydroxychloroquine (HCQ) showed that the AVISE Lupus test impacted physician behavior. In particular, physician certainty in an SLE diagnosis increased with increasing AVISE Lupus scores. Similarly, certainty in an SLE diagnosis decreased when an AVISE Lupus score was negative, indicating that the test helped in both ruling-in and in ruling-out the disease. AVISE Lupus also helped make an accurate diagnosis, both early on and during the course of the study, and higher AVISE Lupus scores led to an increased initiation of HCQ treatment, demonstrating the potential utility of the test in impacting patient management by informing appropriate treatment decisions.Executive Departure • Jun 24Independent Director Jeffrey Elliott has left the companyOn the 17th of June, Jeffrey Elliott's tenure as Independent Director ended after 2.3 years in the role. We don't have any record of a personal shareholding under Jeffrey's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.63 years.Executive Departure • Jun 23Independent Director Jeffrey Elliott has left the companyOn the 17th of June, Jeffrey Elliott's tenure as Independent Director ended after 2.3 years in the role. We don't have any record of a personal shareholding under Jeffrey's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.Reported Earnings • May 13First quarter 2021 earnings released: US$0.48 loss per share (vs US$0.44 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: US$10.6m (up 11% from 1Q 2020). Net loss: US$6.21m (loss widened 12% from 1Q 2020).お知らせ • May 12Exagen Inc. Provides Earnings Guidance for the Fiscal Year 2021Exagen Inc. provided earnings guidance for the fiscal year 2021. For the full year 2021, Exagen reaffirms its prior guidance and expects revenue to be in the range of $47 million to $49 million.Reported Earnings • Mar 18Full year 2020 earnings released: US$1.32 loss per share (vs US$8.46 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$42.0m (up 3.9% from FY 2019). Net loss: US$16.7m (loss narrowed 45% from FY 2019).お知らせ • Mar 17Exagen Inc. Provides Revenue Guidance for the Full Year 2021Exagen Inc. provided revenue guidance for the full year 2021. For the full year 2021, the company expected revenue to be in the range of $47 million to $49 million.Is New 90 Day High Low • Mar 03New 90-day high: €17.10The company is up 39% from its price of €12.30 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €60.55 per share.お知らせ • Mar 03Exagen Inc. to Report Q4, 2020 Results on Mar 16, 2021Exagen Inc. announced that they will report Q4, 2020 results After-Market on Mar 16, 2021Is New 90 Day High Low • Feb 08New 90-day high: €15.20The company is up 17% from its price of €13.00 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €64.96 per share.Is New 90 Day High Low • Jan 23New 90-day high: €14.70The company is up 21% from its price of €12.10 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €71.30 per share.お知らせ • Jan 22Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune DiseasesExagen Inc. announced that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are now a contracted in-network service with Tufts Medical Center, an internationally-respected academic medical center.お知らせ • Jan 05Exagen Inc. Partners with St. Charles Health System, Inc. to Offer AVISE Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune DiseasesExagen Inc. announced that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are a contracted in-network service with St. Charles Health System.Is New 90 Day High Low • Dec 31New 90-day low: €9.20The company is down 1.0% from its price of €9.30 on 02 October 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €60.61 per share.お知らせ • Nov 18Exagen Inc. Extends its Collaboration Agreement with GlaxoSmithKline plcExagen Inc. announced that it has extended its collaboration agreement with GlaxoSmithKline plc, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE® laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential.Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.34 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$10.8m (up 3.2% from 3Q 2019). Net loss: US$4.31m (loss narrowed 75% from 3Q 2019).Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectationsRevenue exceeded analyst estimates by 22%. Over the next year, revenue is forecast to grow 27%, compared to a 4.4% growth forecast for the Healthcare industry in Germany.お知らせ • Nov 11Exagen Inc. Announces Resignation of Chet Burrell from the Board, Effective December 31, 2020On November 6, 2020, Chet Burrell informed the Board of Directors of Exagen Inc. of his decision to resign from the Board, effective December 31, 2020.お知らせ • Nov 04Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection in Collaboration with Brigham and Women’s HospitalExagen Inc. announced a new study in collaboration with Brigham and Women’s Hospital in Boston, MA. As viruses are implicated in the development of autoimmune diseases, there is the need to understand the effects of the current COVID-19 pandemic on the development of rheumatic autoimmune diseases. This study will evaluate the incidence and risk factors for onset of rheumatic autoimmune diseases in people who recovered from COVID-19. Positive polymerase chain reaction (PCR)-confirmed COVID-19 patients from the Brigham will be invited to partake in the year-long evaluation. Patients will be categorized by COVID-19 severity: mild (outpatient), moderate (inpatient, not ICU), and severe (ICU). Patients who elect to participate will be assessed with two validated questionnaires and tested using AVISE® biomarkers to investigate the new onset of rheumatic disease symptoms and autoantibodies in the 3 months to 1 year following onset of COVID-19.お知らせ • Oct 28Exagen Inc. to Report Q3, 2020 Results on Nov 10, 2020Exagen Inc. announced that they will report Q3, 2020 results on Nov 10, 2020お知らせ • Oct 13Exagen Inc. Announces the Publication of Study Evaluating the Economic Benefits AVISE® Lupus TestingExagen Inc. announced the publication of a study evaluating the economic benefits AVISE® Lupus testing, titled “Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis using a Multivariate Assay Panel (MAP)” in ACR Open Rheumatology. Key advancements and findings: First ever evaluation of the economics of diagnosing SLE with AVISE® Lupus (MAP) compared to Standard Diagnostic Laboratory Tests (SDLTs) in a hypothetical cohort of 1,000 suspected SLE patients. Over the four-year time horizon AVISE Lupus demonstrated an estimated total direct cost savings of $1,991,152, or $1,991 per patient. Year 1 savings of $655,403, or $655 per eligible patient, with the use of AVISE® Lupus, which aligns with early benefit to health plans looking for savings in the first year. The diagnosis of SLE is complicated and it takes on average over six years after seeing more than four health care providers; AVISE® Lupus provides a valuable tool to accelerate the diagnosis process. The AVISE® Lupus algorithmic two-tier index utilizes Exagen’s proprietary Cell-Bound Complement Activation Products (CB-CAPs), combined with SLE associated markers, to provide a diagnostic tool with greater sensitivity over C3/C4 and anti-dsDNA and greater specificity over antinuclear antibody (ANA). ACR Open Rheumatology is a peer-reviewed, open access official journal of the American College of Rheumatology. It publishes specialized articles reporting on original investigations of various aspects of rheumatology-related research including basic science, clinical science, epidemiology, health outcomes, and education, as well as reviews and commentaries in the field of rheumatology and related disciplines.お知らせ • Sep 30Exagen Inc. Announces Agreement with Provider Network of America Expanding Access for AVISE® Tests to 8 Million MembersExagen Inc. announced that it has entered into a preferred provider network agreement with Provider Network of America (PNOA). Under the terms of the agreement, over 8 million PNOA members in the U.S. will have in-network access to Exagen’s unique suite of AVISE® tests for autoimmune disorders, including rheumatoid arthritis and lupus. PNOA is a nationwide, direct contracted provider network accessed by 526 payers, which has over 375,000 contracted physicians and 12,000 hospitals and ancillary facilities under contract, assuring reliable access to healthcare for providers, payers and patients. More than 8 million PNOA members have access to PNOA’s preferred provider organization network through a client base consisting of cost containment companies, third party administrators, commercial payers, Taft-Hartley Trust plans and Native American Tribal Plans.Is New 90 Day High Low • Sep 28New 90-day low: €9.15The company is down 8.0% from its price of €9.90 on 30 June 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.67 per share.お知らせ • Sep 24Exagen Inc. Appoints Wendy Johnson as a Class III Director, and to Audit Committee Effective as of October 1, 2020On September 21, 2020, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Exagen Inc. and pursuant to the bylaws of the Company, the Board approved an increase in its authorized size from eight members to nine members and appointed Wendy Johnson to fill the vacancy created by such increase and serve as a Class III director, with an initial term expiring at the Company's 2022 annual meeting of stockholders. The increase and appointment will be effective as of October 1, 2020. In connection with her appointment to the Board, Ms. Johnson was also appointed to the Audit Committee of the Board, effective as of October 1, 2020. Following Ms. Johnson's appointment, the Audit Committee will consist of Jeff Elliott, Wendy Johnson and Tina S. Nova, Ph.D. Wendy Johnson is currently the Chief Operating Officer of Reneo Pharmaceuticals where she is responsible for day-to-day operations, and was instrumental in setting up the company’s UK corporate entity. Ms. Johnson was previously the Interim Chief Operating Officer of AmpliPhi Biosciences Corporation from September 2014 to January 2017, and a member of its board of directors from May 2014 until its merger with C3J Therapeutics (Armata Pharmaceuticals) in May 2019. From 2005 to January 2014, Ms. Johnson served as a venture partner at ProQuest Investments, a venture capital firm. From 2006 to January 2014, Ms. Johnson served as the President and Chief Executive Officer of Aires Pharmaceuticals, a ProQuest portfolio company, until its sale to MAST Therapeutics in 2014.お知らせ • Sep 22Exagen Launches Test to Aid in the Detection of ANCA-Associated Vasculitis (AAV)Exagen Inc. announced the launch of AVISE® Vasculitis AAV, a new testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of ANCA-associated vasculitis (AAV). ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis is a group of autoimmune diseases characterized by vascular inflammation and damage. Early signs and symptoms vary greatly and are not always indicative of the severity of the disease. Rapid and accurate testing is essential to prevent death and long-term disability. AVISE® Vasculitis AAV is intended for use in patients suspected of ANCA-associated vasculitis, otherwise recognized as small vessel diseases: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). AVISE® Vasculitis AAV enhances Exagen’s catalogue of AVISE® tests, allowing physicians further access to Exagen’s specialty lab dedicated to autoimmune diseases.お知らせ • Jul 18Exagen Inc. to Report Q2, 2020 Results on Jul 28, 2020Exagen Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Jul 28, 2020お知らせ • Jul 02Exagen Inc.(NasdaqGM:XGN) dropped from Russell Microcap Value IndexExagen Inc.(NasdaqGM:XGN) dropped from Russell Microcap Value Index株主還元E08ADE BiotechsDE 市場7D12.4%0.9%3.2%1Y-30.4%-12.2%2.5%株主還元を見る業界別リターン: E08A過去 1 年間で-12.2 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: E08Aは、過去 1 年間で2.5 % のリターンを上げたGerman市場を下回りました。価格変動Is E08A's price volatile compared to industry and market?E08A volatilityE08A Average Weekly Movement12.2%Biotechs Industry Average Movement8.7%Market Average Movement6.1%10% most volatile stocks in DE Market13.6%10% least volatile stocks in DE Market2.7%安定した株価: E08Aの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: E08Aの weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2002218John Aballiwww.exagen.comエクサジェン社は、米国でAVISEブランドの各種検査製品の設計、開発、販売を行っています。同社は、全身性エリテマトーデス(SLE)や関節リウマチ(RA)を含む複雑なリウマチ性疾患、自己免疫疾患、自己免疫関連疾患の診断、予後、モニタリングを通じて、医療従事者が患者をケアできるようにする。主な検査製品はAVISE CTDで、様々な結合組織病（CTD）および症状が重複する他の関連疾患を示す症状を呈する患者の鑑別診断を可能にする。AVISEループスプラットフォームは、患者の血液中のCB-CAPsバイオマーカー（EC4dとBC4d）のレベルを定量化することから始まるSLE評価の要であり、AVISE APSはAPSの診断と管理を助ける。さらに、AVISE Vasculitis AAVを提供しており、これは個々の分析物の検査パネルを利用し、抗好中球細胞質抗体関連血管炎の評価とモニタリングの結果を医師に提供するものである；AVISE Anti-Histone: ヒストン蛋白に対する自己抗体の検査、AVISE SLE Prognostic: 腎臓、脳、循環器系に影響を及ぼす合併症の可能性を評価するための自己抗体パネル、AVISE Anti-CarP: バイオマーカーによるRA予後検査。さらに、CB-CAPs技術を用いた血液検査であるAVISE SLE Monitor、特許を取得し検証済みの血液検査であるAVISE MTX、ヒドロキシクロロキンの濃度をモニターする血液検査であるAVISE HCQを提供している。また、アレゲニー・ヘルス・ネットワーク（AHN）研究所とT細胞バイオマーカー開発のための共同研究およびライセンス契約を結んでいる。同社は以前Exagen Diagnostics, Inc.として知られていたが、2019年1月にExagen Inc.に社名を変更した。エクサジェン・インクは2002年に法人化され、カリフォルニア州ビスタに本社を置いている。もっと見るExagen Inc. 基礎のまとめExagen の収益と売上を時価総額と比較するとどうか。E08A 基礎統計学時価総額€88.88m収益（TTM）-€17.38m売上高(TTM)€58.92m1.5xP/Sレシオ-5.1xPER（株価収益率E08A は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計E08A 損益計算書（TTM）収益US$68.38m売上原価US$28.50m売上総利益US$39.88mその他の費用US$60.05m収益-US$20.17m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.83グロス・マージン58.32%純利益率-29.49%有利子負債／自己資本比率158.5%E08A の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 23:13終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Exagen Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Anderson SchockB. Riley Securities, Inc.Mark MassaroBTIGKyle MiksonCanaccord Genuity4 その他のアナリストを表示
お知らせ • May 11Exagen Inc. Reaffirms Earnings Guidance for the full year 2026Exagen Inc. reaffirmed earnings guidance for the full year 2026. The company continues to expect full-year 2026 revenue of $70 million to $73 million.
お知らせ • Apr 28Exagen Inc., Annual General Meeting, Jun 09, 2026Exagen Inc., Annual General Meeting, Jun 09, 2026. Location: training room, 2175 salk avenue, 3rd floor, carlsbad, california 92008, United States
お知らせ • Apr 27Exagen Inc. to Report Q1, 2026 Results on May 11, 2026Exagen Inc. announced that they will report Q1, 2026 results Pre-Market on May 11, 2026
お知らせ • Mar 10Exagen Inc. Provides Earnings Guidance for Full Year 2026Exagen Inc. provided earnings guidance for full year 2026. For the year, the company expects revenue of $70 million to $73 million.
お知らせ • Feb 24Exagen Inc. to Report Q4, 2025 Results on Mar 10, 2026Exagen Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 10, 2026
お知らせ • Jan 12Exagen Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025Exagen Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. For the quarter, the company expects Total Revenue to be $16 million to $17 million. For the year, the company expects Total Revenue to be $66 million to $67 million. Record full year 2025 revenue, an increase of at least 19% over 2024.
お知らせ • May 11Exagen Inc. Reaffirms Earnings Guidance for the full year 2026Exagen Inc. reaffirmed earnings guidance for the full year 2026. The company continues to expect full-year 2026 revenue of $70 million to $73 million.
お知らせ • Apr 28Exagen Inc., Annual General Meeting, Jun 09, 2026Exagen Inc., Annual General Meeting, Jun 09, 2026. Location: training room, 2175 salk avenue, 3rd floor, carlsbad, california 92008, United States
お知らせ • Apr 27Exagen Inc. to Report Q1, 2026 Results on May 11, 2026Exagen Inc. announced that they will report Q1, 2026 results Pre-Market on May 11, 2026
お知らせ • Mar 10Exagen Inc. Provides Earnings Guidance for Full Year 2026Exagen Inc. provided earnings guidance for full year 2026. For the year, the company expects revenue of $70 million to $73 million.
お知らせ • Feb 24Exagen Inc. to Report Q4, 2025 Results on Mar 10, 2026Exagen Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 10, 2026
お知らせ • Jan 12Exagen Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025Exagen Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. For the quarter, the company expects Total Revenue to be $16 million to $17 million. For the year, the company expects Total Revenue to be $66 million to $67 million. Record full year 2025 revenue, an increase of at least 19% over 2024.
お知らせ • Nov 05Exagen Inc. Reiterates Earnings Guidance for the Year 2025Exagen Inc. reiterated earnings guidance for the year 2025. For the year, the company expects revenue of between $65 million and $70 million, and at the high end of the revenue range would expect to achieve positive adjusted EBITDA in the fourth quarter of 2025.
お知らせ • Oct 22Exagen Inc. to Report Q3, 2025 Results on Nov 04, 2025Exagen Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 04, 2025
お知らせ • Jul 29Exagen Inc. Provides Earnings Guidance for the Full Year 2025Exagen Inc. provided earnings guidance for the full year 2025. For the year, company expects 2025 full-year revenue of between $65 million and $70 million, and at the high end of the revenue range would expect to hit positive adjusted EBITDA in the fourth quarter.
お知らせ • Jul 18Exagen Inc. Appoints Charles S. McKhann as A Class III Director and to the Compensation Committee and Nominating Committee, Effective July 17, 2025Exagen Inc.'s board of directors on July 17, 2025, upon the recommendation of the Nominating and Corporate Governance Committee pursuant to the bylaws of the Company, appointed, effective as of July 17, 2025, Charles S. McKhann to serve as a Class III director, with an initial term expiring at the Company’s 2028 annual meeting of stockholders. In connection with and effective as of his appointment to the Board, Mr. McKhann was also appointed to the Compensation Committee of the Board and the Nominating Committee. Also in connection with his appointment, the size of the Board was increased from seven (7) members to eight (8) members, effective as of the Effective Date. Mr. McKhann served as the President, Chief Executive Officer, and a member of the board of directors of Silk Road Medical Inc., a medical device company, from November 2023 to September 2024, when Silk Road was purchased by Boston Scientific Corporation, and served as Chief Executive Officer, President and a member of the Board of Directors of Apollo Endosurgery Inc., a medical device company, from March 2021 to April 4, 2023, when Apollo was purchased by Boston Scientific. From October 2017 to December 2018, Mr. McKhann served as Chief Commercial Officer at ROX Medical Inc., a medical device company. From July 2016 to April 2017, he served as Chief Commercial Officer of Torax Medical Inc., a medical device company acquired by Johnson & Johnson in April 2017. From January 2015 to July 2016, he served as Chief Commercial Officer of Intersect ENT Inc., a medical device company. In addition, from September 2012 to March 2021, he served as Managing Director of Vernon Consulting Inc. Mr. McKhann holds a B.A. in Political Sciences and Economics and an M.B.A. from Stanford University.
お知らせ • Jul 16Exagen Inc. to Report Q2, 2025 Results on Jul 29, 2025Exagen Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 29, 2025
お知らせ • Jun 23Exagen Inc. Appoints Michael Mahler as Chief Scientific OfficerExagen Inc. announced the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune research. At the same time, Dr. Mahler initiated a productive and lasting collaboration with one of his mentors, Dr. Marvin J. Fritzler, a thought leader in the field whose research spans a wide range of topics, including autoimmune disease, the biology of autoantigens, and novel diagnostic technologies. Over the course of his distinguished career, Dr. Mahler has held key positions at various diagnostic companies, most recently serving as Senior Vice President of Research Development and Business Development at Werfen. His transformative work has led to the discovery of several novel autoantigens and the development of innovative diagnostic solutions. His scientific contributions have resulted in over 300 peer-reviewed publications and numerous patents, advancing the accurate diagnosis of autoimmune diseases. In his new role at Exagen, Dr. Mahler will spearhead strategic initiatives aimed at enhancing precision diagnostics for autoimmune diseases. His expertise will support Exagen's development of cutting-edge tools to improve patient outcomes.
お知らせ • May 09Exagen Inc. has completed a Follow-on Equity Offering in the amount of $17.5875 million.Exagen Inc. has completed a Follow-on Equity Offering in the amount of $17.5875 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,350,000 Price\Range: $5.25 Discount Per Security: $0.315
お知らせ • May 08Exagen Inc. has filed a Follow-on Equity Offering.Exagen Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock
お知らせ • May 06Exagen Inc. Provides Earnings Guidance for Full Year 2025Exagen Inc. provided earnings guidance for full year 2025. For the full-year, the company expects revenue of at least $65 million.
お知らせ • May 01Exagen Inc., Annual General Meeting, Jun 10, 2025Exagen Inc., Annual General Meeting, Jun 10, 2025. Location: exagen administrative offices, training room, 2175 salk avenue, 3rd floor,california 92008., carlsbad United States
お知らせ • Apr 22Exagen Inc. to Report Q1, 2025 Results on May 05, 2025Exagen Inc. announced that they will report Q1, 2025 results Pre-Market on May 05, 2025
お知らせ • Mar 12Exagen Inc. Provides Earnings Guidance for First Quarter of 2025Exagen Inc. provides earnings guidance for first quarter of 2025. For the period, the company expects total revenue of at least $14.5 million. The company expects to provide its full-year 2025 financial outlook in connection with the release of its first quarter 2025 financial results.
お知らせ • Feb 26Exagen Inc. to Report Q4, 2024 Results on Mar 11, 2025Exagen Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 11, 2025
お知らせ • Jan 13Exagen Inc. Secures Conditional Ny State Approval for New Lupus and Rheumatoid Arthritis BiomarkersExagen Inc. announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays, with a planned commercial launch in January 2025. New AVISE CTD Biomarkers, The company’s new SLE and RA biomarkers will be incorporated into the AVISE CTD platform. Collectively, the company expects these new biomarkers will further improve the clinical utility of AVISE CTD, and provide clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. The new biomarkers are as follows: T-Cell Lupus profile comprises new biomarkers; TC4d, TIgG, and TIgM. These markers provide superior sensitivity for SLE compared to conventional SLE biomarkers, further enhancing their AVISE Lupus profile for a more comprehensive diagnosis, particularly in clinically ambiguous cases. RA profile includes additional anti-RA33 biomarkers; IgA, IgG, and IgM. These markers provide clinicians with more data to confidently identify patients with RA and substantiate a seronegative RA diagnosis.
お知らせ • Nov 15Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD PlatformExagen Inc. announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) biomarkers, to be incorporated into the AVISE CTD platform. Collectively, these new biomarkers will further improve the clinical utility of AVISE CTD, providing clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. Since 2012, AVISE CTD has delivered diagnostic clarity where overlapping clinical symptoms and ambiguous disease states make it difficult to arrive at a differential diagnosis of a connective tissue disease (CTD). A lack of diagnostic clarity may lead to serial and repeat testing, increased morbidity, worsening mortality rates and growing healthcare costs. The seven new biomarkers for AVISE CTD are as follows: A new T Cell Lupus profile will include three new T Cell biomarkers (TC4d, TIgG, TIgM). These provide enhanced sensitivity for SLE as compared to conventional SLE biomarkers and serve as a complement to the AVISE Lupus profile also included in the test. · The RA profile will be enhanced with the addition of four biomarkers (anti-CarP and anti-RA33 biomarkers IgA, IgG, IgM). Providers are given more data to confidently identify patients with RA and substantiate a seronegative RA diagnosis. The AVISE CTD test that rheumatologists have come to know and trust is composed of multiple biomarker assays that assist in the clinical diagnosis of the most common CTDs, which included: SLE; RA; Sjögren's Disease; Mixed Connective Tissue Disease (MCTD); Antiphospholipid Syndrome; Myositis; Systemic Sclerosis; Graves’ Disease; Hashimoto’s Thyroiditis. Availability of the AVISE CTD test enhancements are pending conditional approval by the New York State Department of Health. Learn more about AVISE CTD [2] and its ability to provide unique diagnostic clarity.
Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.31 loss in 3Q 2023)Third quarter 2024 results: US$0.28 loss per share (improved from US$0.31 loss in 3Q 2023). Revenue: US$12.5m (down 6.8% from 3Q 2023). Net loss: US$5.03m (loss narrowed 7.1% from 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
お知らせ • Nov 13Exagen Inc. Provides Earnings Guidance for the Full Year 2024Exagen Inc. provided earnings guidance for the full year 2024. The company now expected 2024 full-year revenue of $55 million to $56 million, primarily reflecting the impact of one-time adjustments in the third quarter.
お知らせ • Oct 30Exagen Inc. to Report Q3, 2024 Results on Nov 12, 2024Exagen Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 12, 2024
New Risk • Aug 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (€53.8m market cap, or US$58.8m).
Reported Earnings • Aug 06Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.28 loss in 2Q 2023)Second quarter 2024 results: US$0.16 loss per share (improved from US$0.28 loss in 2Q 2023). Revenue: US$15.1m (up 6.6% from 2Q 2023). Net loss: US$2.97m (loss narrowed 41% from 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • Aug 06Exagen Inc. Revises Earnings Guidance for the Full Year 2024Exagen Inc. revised earnings guidance for the full year 2024. Given continued improved performance, the company increasing guidance for full-year 2024 revenue to at least $57 million.
お知らせ • Aug 03Exagen Inc. Announces Chief Financial Officer ChangesExagen Inc. announced the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. Mr. Black brings to Exagen more than 30 years of financial and accounting experience, having served in finance leadership roles for eight publicly traded companies. He currently serves as CFO of Standard BioTools, where he recently played a key leadership role in executing its merger with SomaLogic, creating a diversified leader in life science tools. Prior to that, he was CFO of Apollo Endosurgery, where he was instrumental in the Company turnaround and eventual $650 million sale to Boston Scientific. Previously, he spent over four years as CFO of Alphatec Spine, where he successfully closed nearly $500M in financing transactions to support accelerated growth, two strategic acquisitions and expansion of the company market cap from $20M to over $1B during his tenure. Previously to this role, Mr. Black served as Senior Vice President and Chief Financial Officer of Apollo Endosurgery Inc., a publicly traded, medical technology company focused on endoscopic therapies for gastrointestinal conditions and interventional treatment of obesity, from August 2021 until April 2023, when Apollo was acquired by Boston Scientific. Prior to joining Apollo, he served as Executive Vice President and Chief Financial Officer of Alphatec Holdings Inc., a publicly traded, medical technology company focused on the surgical treatment of spinal disorders, from March 2017 to April 2021. Prior to joining Alphatec, Mr. Black was Senior Vice President and Chief Financial Officer of Applied Proteomics Inc., a proteomics-based diagnostics company, Senior Vice President and Chief Financial Officer of AltheaDx Inc., a pharmacogenetics diagnostics company, and Senior Vice President and Chief Financial Officer of Verenium Corporation, an industrial biotechnology company. Mr. Black began his career at Ernst & Young LLP. Mr. Black is a member of the board of directors of Cellana Inc., a privately held company and developer of algae-based bioproducts, where he serves as chairperson of the audit committee. Mr. Black received his B.S. in Business from the University of Arizona.
お知らせ • Jul 22Exagen Inc. to Report Q2, 2024 Results on Aug 05, 2024Exagen Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 05, 2024
Recent Insider Transactions • May 19CEO, President & Director recently bought €71k worth of stockOn the 16th of May, John Aballi bought around 40k shares on-market at roughly €1.77 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of €16k worth in shares.
お知らせ • May 15Exagen Inc. Updates Earnings Guidance for the Full Year 2024Exagen Inc. updated earnings guidance for the full year 2024. For full year 2024 revenue, company is increasing guidance to at least $55 million.
Reported Earnings • May 13First quarter 2024 earnings released: US$0.19 loss per share (vs US$0.44 loss in 1Q 2023)First quarter 2024 results: US$0.19 loss per share (improved from US$0.44 loss in 1Q 2023). Revenue: US$14.4m (up 28% from 1Q 2023). Net loss: US$3.36m (loss narrowed 56% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
お知らせ • May 01Exagen Inc. to Report Q1, 2024 Results on May 13, 2024Exagen Inc. announced that they will report Q1, 2024 results at 9:30 AM, US Eastern Standard Time on May 13, 2024
お知らせ • Apr 28Exagen Inc., Annual General Meeting, Jun 10, 2024Exagen Inc., Annual General Meeting, Jun 10, 2024, at 06:00 Pacific Standard Time. Location: Exagen Administrative Offices, Training Room, 2175 Salk Avenue, 3rd Floor, Carlsbad California United States Agenda: To elect three directors to serve as Class II directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified; to ratify the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
お知らせ • Apr 27Exagen Inc. Announces Changes in Board of DirectorsExagen Inc. announced changes to the Board of Directors. Exagen announced Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the University of Illinois. He spent over 10 years at the scientific software company, Accelrys, where he held several positions with increasing responsibility including SVP, General Manager and Chief Science Officer. He then joined Illumina as its first Chief Information Officer and spent 12 years with the sequencing leader. He was most recently with LunaPBC as the Chief Information and Privacy Officer. Dr. Kahn currently holds Board positions at Blue Circle Health, Rady Children’s Institute for Genomic Medicine and Rady Children's Hospital. Dr. Kahn received a B.S. in Chemistry from Rider College, a Ph.D. in Theoretical Organic Chemistry from the University of California, Irvine and was a Fellow Commoner at Churchill College and Postdoctoral Fellow at the University of Cambridge, England. Additionally, in an ever-continuing effort to streamline operations at the company, Exagen announced that it is reducing the size of the Board of Directors from nine to seven, a change that has been carefully planned and complements the long-term strategy. Brian Birk, Ebetuel Pallares, Ph.D. and Wendy Johnson have all agreed to step down from the Board of Directors, effective on the date of the annual shareholder meeting on June 10th, 2024.
Reported Earnings • Mar 19Full year 2023 earnings released: US$1.34 loss per share (vs US$2.77 loss in FY 2022)Full year 2023 results: US$1.34 loss per share (improved from US$2.77 loss in FY 2022). Revenue: US$52.5m (up 15% from FY 2022). Net loss: US$23.7m (loss narrowed 50% from FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.
New Risk • Mar 19New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings are forecast to decline by an average of 2.0% per year for the foreseeable future. Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$30m). Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Shareholders have been diluted in the past year (4.5% increase in shares outstanding). Market cap is less than US$100m (€27.8m market cap, or US$30.2m).
お知らせ • Mar 08Exagen Inc. to Report Q4, 2023 Results on Mar 18, 2024Exagen Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 18, 2024
お知らせ • Jan 08Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023Exagen Inc. reaffirmed earnings guidance for the full year ended December 31, 2023. For the year, the company expected total revenue of at least $50 million.
Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.47 loss in 3Q 2022)Third quarter 2023 results: US$0.31 loss per share (improved from US$0.47 loss in 3Q 2022). Revenue: US$13.4m (down 8.9% from 3Q 2022). Net loss: US$5.42m (loss narrowed 33% from 3Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
お知らせ • Oct 31Exagen Inc. to Report Q3, 2023 Results on Nov 13, 2023Exagen Inc. announced that they will report Q3, 2023 results After-Market on Nov 13, 2023
Recent Insider Transactions • Oct 20CEO, President & Director recently sold €56k worth of stockOn the 17th of October, John Aballi sold around 34k shares on-market at roughly €1.65 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite the recent sale, John has been a net buyer over the last 12 months, purchasing a net total of €173k worth of shares.
New Risk • Aug 08New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$34m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$34m). Currently unprofitable and not forecast to become profitable over next 3 years (US$26m net loss in 3 years). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€42.0m market cap, or US$46.0m).
Reported Earnings • Aug 08Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.86 loss in 2Q 2022)Second quarter 2023 results: US$0.28 loss per share (improved from US$0.86 loss in 2Q 2022). Revenue: US$14.1m (up 86% from 2Q 2022). Net loss: US$5.01m (loss narrowed 66% from 2Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings.
New Risk • Aug 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.7% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$26m net loss in 3 years). Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€37.7m market cap, or US$41.4m).
お知らせ • Jul 26Exagen Inc. to Report Q2, 2023 Results on Aug 07, 2023Exagen Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 07, 2023
お知らせ • Jul 25Exagen Inc. Appoints Paul Kim as Class II DirectorOn July 24, 2023, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the board) of Exagen Inc., and pursuant to the bylaws of the Company, the Board appointed Paul Kim to serve as a Class II director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling the vacancy on the Board. In connection with his appointment to the Board, Mr. Kim was also appointed to the Audit Committee of the Board (the “Audit Committee) and the Compensation Committee of the Board (the Compensation Committee), effective as of July 24, 2023. Following Mr. Kim’s appointment, the Audit Committee consists of Frank Stokes (Chair), Wendy Johnson, Ana Hooker and Paul Kim, and the Compensation Committee consists of Bruce C. Robertson, Ph.D. (Chair), Ana Hooker and Paul Kim. Paul Kim has served as Fulgent Genetic Inc.’s (Fulgent) Chief Financial Officer since January 2016. Prior to his service for Fulgent, Mr. Kim was retired from 2011 until 2015 and served as Chief Financial Officer of Cogent Inc., a publicly traded biometric identification services and product company, from 2004 until 2011. Mr. Kim’s past experience also includes service as the Chief Financial Officer of JNI Corporation, a publicly traded storage area network technology company, from 2002 until 2003, as Vice President, Finance and Corporate Controller at JNI from October 1999 to August 2002 and as Vice President of Finance and Administration for Datafusion Inc., a privately held software development company, from 1998 until 1999. From April 1996 to January 1998, Mr. Kim was the Corporate Controller for Interlink Computer Sciences Inc., a publicly traded enterprise software company. From 1990 to 1996, Mr. Kim worked for Coopers and Lybrand L.L.P., leaving as an audit manager. Mr. Kim received a B.A. in Economics from the University of California at Berkeley in 1989 and is a Certified Public Accountant.
Reported Earnings • May 16First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.60 loss in 1Q 2022)First quarter 2023 results: US$0.44 loss per share (improved from US$0.60 loss in 1Q 2022). Revenue: US$11.2m (up 8.0% from 1Q 2022). Net loss: US$7.69m (loss narrowed 25% from 1Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 21Full year 2022 earnings released: US$2.77 loss per share (vs US$1.68 loss in FY 2021)Full year 2022 results: US$2.77 loss per share (further deteriorated from US$1.68 loss in FY 2021). Revenue: US$45.6m (down 5.7% from FY 2021). Net loss: US$47.4m (loss widened 77% from FY 2021). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.
お知らせ • Jan 24Exagen Inc. Announces Board ChangesExagen Inc. announced that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board.Dr. Nova currently serves as President of Veracyte's U.S. CLIA business where she leads all aspects of the company's broad menu of diagnostic laboratory tests. She previously held the position of President & CEO of Decipher Biosciences until March 2021, when Veracyte purchased the organization for $600 million. She has held numerous leadership roles in the life science industry, which include CEO of Molecular Stethoscope and SVP & General Manager of Oncology at Illumina. Dr. Nova was the co-founder, President & CEO of Genoptix, which was purchased by Novartis AG for $470 million in 2011. She has also held senior positions with Nanogen Inc., Ligand Pharmaceuticals Inc. and Hybritech. Dr. Nova currently serves on the Board of Azenta and previously served on the Board of Directors of Veracyte and Arena Pharmaceuticals. Dr. Nova holds a Ph.D. in Biochemistry from the University of California, Riverside and a B.S. in Biological Sciences from the University of California, Irvine.
お知らせ • Dec 06Exagen Inc. Announces Executive ChangesExagen Inc. announced that on December 5, 2022, Debra Zack, M.D., Ph.D., the company’s Chief Medical Officer, was removed from her position and her employment terminated in connection with the Reduction in Force. Dr. Zack is entitled to severance under that certain Amended and Restated Executive Change in Control and Severance Plan. On December 5, 2022, Mark Hazeltine, the Company’s current Chief Operating Officer was appointed to serve as the Company’s Chief Business Officer. Mr. Hazeltine has served as the company’s Chief Operating Officer since March 2021 and served in multiple key leadership roles including General Manager, Senior Vice President of Finance and Corporate Development, Vice President of Finance, and Senior Director of Financial Planning and Analysis since joining the Company in March 2015. Prior to joining the Company, from September 2010 to March 2015, Mr. Hazeltine served as Director of Financial Planning and Analysis and Director of Financial Business Processes at CareFusion. Mr. Hazeltine also worked in multiple management roles at multinational organizations including Kyocera and Qualcomm. Mr. Hazeltine received a B.A. in Business Administration from the University of San Diego and an M.B.A. from the Marshall School of Business at the University of Southern California.
お知らせ • Nov 16Exagen Inc. Increases Revenue Guidance for 2022Exagen Inc. increased revenue guidance for 2022. For the period, the company increases revenue guidance range to $40 million to $43 million.
お知らせ • Nov 15Exagen Inc. announced delayed 10-Q filingOn 11/14/2022, Exagen Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 01Exagen Inc. to Report Q3, 2022 Results on Nov 14, 2022Exagen Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 14, 2022
お知らせ • Oct 18+ 1 more updateExagen Inc. Appoints John Aballi as PresidentExagen Inc. announced that the company has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm. The Exagen Board has appointed Mr. Aballi as CEO, President, and a member of the Board. Mr. Aballi is an executive with a broad range of experience in growth-stage companies in the clinical diagnostics arena. Most recently he served as SVP, General Manager, Urology & CLIA COO at Veracyte Inc. Mr. Aballi, who has 15 years of diagnostic industry experience, is known for transforming commercial and laboratory operations and has broad experience building efficient clinical diagnostics operations. In his previous role at Veracyte, he was responsible for a business unit of 245 members and led a team that grew the urology unit revenue to $120 million-plus annually. He also led the implementation of CAP standards across the San Francisco and Austin labs and managed Veracyte's CLIA laboratory operations. In his prior position, Mr. Aballi was COO at Decipher Biosciences where he oversaw revenue growth from $12.6 million in 2018 to $39 million in 2020. Mr. Aballi was a key part of the executive team that helped take Decipher from a struggling company to being sold to Veracyte for $600 million in early 2021. He had P&L responsibility for all aspects of operations including sales, quality management, medical operations, customer service, IT, assay development, billing, managed care, internal expansion, and laboratory operations. Mr. Aballi was also responsible for oversight of laboratory operations at Molecular Stethoscope and Genoptix in various senior roles. Mr. Aballi was a Board Member of PFS Genomics in San Diego, a molecular diagnostic company specializing in proprietary signature development in breast cancer, which was acquired by Exact Sciences in 2021. He holds an MBA from California Baptist University and dual degrees from UC San Diego in biochemistry and cell biology and economics. Mr. Aballi will assume his new role at Exagen immediately.
お知らせ • Oct 05Exagen Inc. Appoints Andrew L. Concoff as Chief Innovation OfficerExagen Inc. announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as Chief Innovation Officer. In this role, Dr. Concoff will lead the company’s rheumatoid arthritis medical initiatives, including the AVISE® RADR platform (Rheumatoid Arthritis Drug Response). Dr. Concoff will be a key principal in strategy, business development, portfolio management, pipeline prioritization, and formation of new business ventures, as well as the advancement of innovative access partnerships with payors and governments globally. Dr. Concoff has more than fifteen years of clinical practice in rheumatology, having completed his fellowship at the University of California, Los Angeles. He earned a B.S. in Psychobiology from UCLA, an M.D. from the University of Texas Medical School at Houston where he also completed coursework toward a Master’s in Clinical Research. Dr. Concoff joins Exagen from United Rheumatology, where his work as Executive Vice President, Chief Medical Officer enables him to create, model, and implement value-based programs with payors, quality improvement initiatives with pharmaceutical manufacturers, and other clinical care innovations with stakeholders across the musculoskeletal ecosystem. He is also a Fellow of the American College of Rheumatology and has served on numerous national guideline committees, most recently as Chair of the Knee Osteoarthritis and Ultrasound Guideline Committees for United Rheumatology.
お知らせ • Sep 02Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 PatientsExagen Inc. announced that its collaboration with Dr. Iñaki Sanz at Emory University has led to a publication in Nature, found here. Exagen’s clinical test offerings, run on samples from severe COVID-19 patients, helped researchers from Emory characterize the autoimmune profiles induced by SARS-CoV-2 infection. In addition, these retrospective analyses laid the groundwork for the recent longitudinal studies of so-called post-acute COVID syndrome (PACS), as well as other post-severe pulmonary infection sequelae, including the incorporation of Exagen’s proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. These efforts will assess the importance of long-term autoimmune monitoring in those patients experiencing lasting symptoms following acute pulmonary infection, including those caused by SARS-CoV-2.
Reported Earnings • Aug 06Second quarter 2022 earnings released: US$0.78 loss per share (vs US$0.38 loss in 2Q 2021)Second quarter 2022 results: US$0.78 loss per share (down from US$0.38 loss in 2Q 2021). Revenue: US$8.96m (down 30% from 2Q 2021). Net loss: US$13.3m (loss widened 108% from 2Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 24% growth forecast for the industry in Germany.
お知らせ • Aug 06+ 1 more updateExagen Inc. Provides Revenue Guidance for the Year of 2022Exagen Inc. provided revenue guidance for the year of 2022. For the year, the company expected revenue to be in the range of $35 million to $40 million.
お知らせ • Jul 22Exagen Inc. to Report Q2, 2022 Results on Aug 04, 2022Exagen Inc. announced that they will report Q2, 2022 results After-Market on Aug 04, 2022
Reported Earnings • May 13First quarter 2022 earnings released: US$0.60 loss per share (vs US$0.48 loss in 1Q 2021)First quarter 2022 results: US$0.60 loss per share (down from US$0.48 loss in 1Q 2021). Revenue: US$10.4m (down 1.8% from 1Q 2021). Net loss: US$10.3m (loss widened 65% from 1Q 2021). Over the next year, revenue is forecast to grow 17%, compared to a 37% growth forecast for the industry in Germany.
お知らせ • May 12+ 1 more updateExagen Inc. Revises Revenue Guidance for the Full Year of 2022Exagen Inc. revised revenue guidance for the full year of 2022. For the year, the company raises its guidance and expects revenue to be in the range of $53 million to $55 million, compared to previously provided guidance of $51 million to $53 million.
お知らせ • Apr 26Exagen Inc. to Report Q1, 2022 Results on May 11, 2022Exagen Inc. announced that they will report Q1, 2022 results After-Market on May 11, 2022
Reported Earnings • Nov 11Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.34 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$12.3m (up 14% from 3Q 2020). Net loss: US$7.18m (loss widened 67% from 3Q 2020).
Reported Earnings • Aug 11Second quarter 2021 earnings released: US$0.38 loss per share (vs US$0.27 loss in 2Q 2020)The company reported a mediocre second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$12.8m (up 43% from 2Q 2020). Net loss: US$6.41m (loss widened 91% from 2Q 2020).
お知らせ • Jul 15Exagen Inc. Announces the Publication of Their Latest Clinical Utility Study in Lupus & Science MedicineExagen Inc. announced the publication of their latest clinical utility study in Lupus & Science Medicine. This multi-center study demonstrated that the AVISE Lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (SLE) in patients suspected of this disease and informed appropriate treatment decisions. In collaboration with 12 rheumatology practices, a systematic and longitudinal review of medical records of patients that received AVISE testing between 2018 and 2020 was performed. Medical records of antinuclear antibody (ANA)-positive patients with a positive or negative AVISE Lupus score were evaluated at three time points: when the test was ordered, when the test results were reviewed, and at least 8 months later. Assessment of the confidence in the diagnosis of SLE and initiation of hydroxychloroquine (HCQ) showed that the AVISE Lupus test impacted physician behavior. In particular, physician certainty in an SLE diagnosis increased with increasing AVISE Lupus scores. Similarly, certainty in an SLE diagnosis decreased when an AVISE Lupus score was negative, indicating that the test helped in both ruling-in and in ruling-out the disease. AVISE Lupus also helped make an accurate diagnosis, both early on and during the course of the study, and higher AVISE Lupus scores led to an increased initiation of HCQ treatment, demonstrating the potential utility of the test in impacting patient management by informing appropriate treatment decisions.
Executive Departure • Jun 24Independent Director Jeffrey Elliott has left the companyOn the 17th of June, Jeffrey Elliott's tenure as Independent Director ended after 2.3 years in the role. We don't have any record of a personal shareholding under Jeffrey's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.63 years.
Executive Departure • Jun 23Independent Director Jeffrey Elliott has left the companyOn the 17th of June, Jeffrey Elliott's tenure as Independent Director ended after 2.3 years in the role. We don't have any record of a personal shareholding under Jeffrey's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.
Reported Earnings • May 13First quarter 2021 earnings released: US$0.48 loss per share (vs US$0.44 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: US$10.6m (up 11% from 1Q 2020). Net loss: US$6.21m (loss widened 12% from 1Q 2020).
お知らせ • May 12Exagen Inc. Provides Earnings Guidance for the Fiscal Year 2021Exagen Inc. provided earnings guidance for the fiscal year 2021. For the full year 2021, Exagen reaffirms its prior guidance and expects revenue to be in the range of $47 million to $49 million.
Reported Earnings • Mar 18Full year 2020 earnings released: US$1.32 loss per share (vs US$8.46 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$42.0m (up 3.9% from FY 2019). Net loss: US$16.7m (loss narrowed 45% from FY 2019).
お知らせ • Mar 17Exagen Inc. Provides Revenue Guidance for the Full Year 2021Exagen Inc. provided revenue guidance for the full year 2021. For the full year 2021, the company expected revenue to be in the range of $47 million to $49 million.
Is New 90 Day High Low • Mar 03New 90-day high: €17.10The company is up 39% from its price of €12.30 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €60.55 per share.
お知らせ • Mar 03Exagen Inc. to Report Q4, 2020 Results on Mar 16, 2021Exagen Inc. announced that they will report Q4, 2020 results After-Market on Mar 16, 2021
Is New 90 Day High Low • Feb 08New 90-day high: €15.20The company is up 17% from its price of €13.00 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €64.96 per share.
Is New 90 Day High Low • Jan 23New 90-day high: €14.70The company is up 21% from its price of €12.10 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €71.30 per share.
お知らせ • Jan 22Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune DiseasesExagen Inc. announced that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are now a contracted in-network service with Tufts Medical Center, an internationally-respected academic medical center.
お知らせ • Jan 05Exagen Inc. Partners with St. Charles Health System, Inc. to Offer AVISE Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune DiseasesExagen Inc. announced that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are a contracted in-network service with St. Charles Health System.
Is New 90 Day High Low • Dec 31New 90-day low: €9.20The company is down 1.0% from its price of €9.30 on 02 October 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €60.61 per share.
お知らせ • Nov 18Exagen Inc. Extends its Collaboration Agreement with GlaxoSmithKline plcExagen Inc. announced that it has extended its collaboration agreement with GlaxoSmithKline plc, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE® laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential.
Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.34 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$10.8m (up 3.2% from 3Q 2019). Net loss: US$4.31m (loss narrowed 75% from 3Q 2019).
Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectationsRevenue exceeded analyst estimates by 22%. Over the next year, revenue is forecast to grow 27%, compared to a 4.4% growth forecast for the Healthcare industry in Germany.
お知らせ • Nov 11Exagen Inc. Announces Resignation of Chet Burrell from the Board, Effective December 31, 2020On November 6, 2020, Chet Burrell informed the Board of Directors of Exagen Inc. of his decision to resign from the Board, effective December 31, 2020.
お知らせ • Nov 04Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection in Collaboration with Brigham and Women’s HospitalExagen Inc. announced a new study in collaboration with Brigham and Women’s Hospital in Boston, MA. As viruses are implicated in the development of autoimmune diseases, there is the need to understand the effects of the current COVID-19 pandemic on the development of rheumatic autoimmune diseases. This study will evaluate the incidence and risk factors for onset of rheumatic autoimmune diseases in people who recovered from COVID-19. Positive polymerase chain reaction (PCR)-confirmed COVID-19 patients from the Brigham will be invited to partake in the year-long evaluation. Patients will be categorized by COVID-19 severity: mild (outpatient), moderate (inpatient, not ICU), and severe (ICU). Patients who elect to participate will be assessed with two validated questionnaires and tested using AVISE® biomarkers to investigate the new onset of rheumatic disease symptoms and autoantibodies in the 3 months to 1 year following onset of COVID-19.
お知らせ • Oct 28Exagen Inc. to Report Q3, 2020 Results on Nov 10, 2020Exagen Inc. announced that they will report Q3, 2020 results on Nov 10, 2020
お知らせ • Oct 13Exagen Inc. Announces the Publication of Study Evaluating the Economic Benefits AVISE® Lupus TestingExagen Inc. announced the publication of a study evaluating the economic benefits AVISE® Lupus testing, titled “Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis using a Multivariate Assay Panel (MAP)” in ACR Open Rheumatology. Key advancements and findings: First ever evaluation of the economics of diagnosing SLE with AVISE® Lupus (MAP) compared to Standard Diagnostic Laboratory Tests (SDLTs) in a hypothetical cohort of 1,000 suspected SLE patients. Over the four-year time horizon AVISE Lupus demonstrated an estimated total direct cost savings of $1,991,152, or $1,991 per patient. Year 1 savings of $655,403, or $655 per eligible patient, with the use of AVISE® Lupus, which aligns with early benefit to health plans looking for savings in the first year. The diagnosis of SLE is complicated and it takes on average over six years after seeing more than four health care providers; AVISE® Lupus provides a valuable tool to accelerate the diagnosis process. The AVISE® Lupus algorithmic two-tier index utilizes Exagen’s proprietary Cell-Bound Complement Activation Products (CB-CAPs), combined with SLE associated markers, to provide a diagnostic tool with greater sensitivity over C3/C4 and anti-dsDNA and greater specificity over antinuclear antibody (ANA). ACR Open Rheumatology is a peer-reviewed, open access official journal of the American College of Rheumatology. It publishes specialized articles reporting on original investigations of various aspects of rheumatology-related research including basic science, clinical science, epidemiology, health outcomes, and education, as well as reviews and commentaries in the field of rheumatology and related disciplines.
お知らせ • Sep 30Exagen Inc. Announces Agreement with Provider Network of America Expanding Access for AVISE® Tests to 8 Million MembersExagen Inc. announced that it has entered into a preferred provider network agreement with Provider Network of America (PNOA). Under the terms of the agreement, over 8 million PNOA members in the U.S. will have in-network access to Exagen’s unique suite of AVISE® tests for autoimmune disorders, including rheumatoid arthritis and lupus. PNOA is a nationwide, direct contracted provider network accessed by 526 payers, which has over 375,000 contracted physicians and 12,000 hospitals and ancillary facilities under contract, assuring reliable access to healthcare for providers, payers and patients. More than 8 million PNOA members have access to PNOA’s preferred provider organization network through a client base consisting of cost containment companies, third party administrators, commercial payers, Taft-Hartley Trust plans and Native American Tribal Plans.
Is New 90 Day High Low • Sep 28New 90-day low: €9.15The company is down 8.0% from its price of €9.90 on 30 June 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.67 per share.
お知らせ • Sep 24Exagen Inc. Appoints Wendy Johnson as a Class III Director, and to Audit Committee Effective as of October 1, 2020On September 21, 2020, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Exagen Inc. and pursuant to the bylaws of the Company, the Board approved an increase in its authorized size from eight members to nine members and appointed Wendy Johnson to fill the vacancy created by such increase and serve as a Class III director, with an initial term expiring at the Company's 2022 annual meeting of stockholders. The increase and appointment will be effective as of October 1, 2020. In connection with her appointment to the Board, Ms. Johnson was also appointed to the Audit Committee of the Board, effective as of October 1, 2020. Following Ms. Johnson's appointment, the Audit Committee will consist of Jeff Elliott, Wendy Johnson and Tina S. Nova, Ph.D. Wendy Johnson is currently the Chief Operating Officer of Reneo Pharmaceuticals where she is responsible for day-to-day operations, and was instrumental in setting up the company’s UK corporate entity. Ms. Johnson was previously the Interim Chief Operating Officer of AmpliPhi Biosciences Corporation from September 2014 to January 2017, and a member of its board of directors from May 2014 until its merger with C3J Therapeutics (Armata Pharmaceuticals) in May 2019. From 2005 to January 2014, Ms. Johnson served as a venture partner at ProQuest Investments, a venture capital firm. From 2006 to January 2014, Ms. Johnson served as the President and Chief Executive Officer of Aires Pharmaceuticals, a ProQuest portfolio company, until its sale to MAST Therapeutics in 2014.
お知らせ • Sep 22Exagen Launches Test to Aid in the Detection of ANCA-Associated Vasculitis (AAV)Exagen Inc. announced the launch of AVISE® Vasculitis AAV, a new testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of ANCA-associated vasculitis (AAV). ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis is a group of autoimmune diseases characterized by vascular inflammation and damage. Early signs and symptoms vary greatly and are not always indicative of the severity of the disease. Rapid and accurate testing is essential to prevent death and long-term disability. AVISE® Vasculitis AAV is intended for use in patients suspected of ANCA-associated vasculitis, otherwise recognized as small vessel diseases: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). AVISE® Vasculitis AAV enhances Exagen’s catalogue of AVISE® tests, allowing physicians further access to Exagen’s specialty lab dedicated to autoimmune diseases.
お知らせ • Jul 18Exagen Inc. to Report Q2, 2020 Results on Jul 28, 2020Exagen Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Jul 28, 2020
お知らせ • Jul 02Exagen Inc.(NasdaqGM:XGN) dropped from Russell Microcap Value IndexExagen Inc.(NasdaqGM:XGN) dropped from Russell Microcap Value Index
